When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AGN - Kala's Upcoming NDA Submission For EYSUVIS Is A Great Catalyst Opportunity
Allergan plc
Kala Pharmaceuticals (KALA) announced that it had achieved positive results from its phase 3 study using EYSUVIS for the treatment of patients with dry eye disease. It had trouble in the past with its first NDA of this drug, because it had received a CRL. Now that the biotech has been able to complete its most recent phase 3 study, it can resubmit its NDA to the FDA for potential approval for this drug. The dry eye disease market is large and this should definitely cause the stock to trade higher in the